Form 51-102F3

MATERIAL CHANGE REPORT

Item 1. Name and Address of Reporting Issuer

Noveris Health Sciences Inc. (the "Company")
1500-1055 West Georgia Street
Vancouver, BC V6E 4N7

Item 2. Date of Material Change

March 18, 2026

Item 3. News Release

A news release was disseminated on March 18, 2026, through the Newswire and subsequently filed on SEDAR+.

Item 4. Summary of Material Changes

The Company closed a non-brokered private placement through the issuance of 9,625,049 units (each, a "Unit") at a price of $0.24 per Unit for gross proceeds of $2,310,011.76 (the "Offering").

Item 5. Full Description of Material Change

Item 5.1 Full Description of Material Change

The Company closed the Offering. Each Unit consists of: (i) one common share of the Company and (ii) one common share purchase warrant, with each warrant entitling the holder thereof to acquire one additional common share of the Company at an exercise price of $0.30 for a period of 24 from the date of issuance.

The Units (and underlying securities comprising the Units) were issued pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions and will not be subject to statutory hold periods in compliance with Canadian securities laws.

In connection with the Offering, the Company paid an aggregate of $28,050.60 in cash finder's fees to arm's length finders.

The proceeds raised from the Offering are intended to be used for general working capital, general and administrative expenses, and research and development.

Item 5.2 Disclosure for Restructuring Transactions

Not applicable

Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

Not applicable.

Item 8. Executive Officer

For further information, please contact:

Jason Birmingham
Chief Executive Officer
+1 778-900- 6877
Jason0612@gmail.com

Item 9. **Date of Report**

March 23, 2026